Mission

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus (HCV), or other viral infections through highquality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Board of Directors

Nonstaff board members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. As part of its duties, the board oversees the needs assessment, design, development, and evaluation of all educational programs. Visit www.iasusa.org/about/ias-usa-board-ofdirectors/ for a list of Board of Directors members.

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

 These full-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. These courses are held in several US cities each year. Visit www.iasusa.org/activities/live-courses/hivcourses/ for upcoming courses.

A Small-Group Workshop on Evolving Strategies in Hepatitis C Management

 These half-day CME workshops are designed to improve the clinical care of people with hepatitis C. The small-group interactive workshops are limited to 50 clinical decision makers (physicians, nurse practitioners, PharmDs, and physician assistants). A limited number of spots are reserved for registered nurses who are the primary clinical decision makers in their clinics or practices. Visit www.iasusa.org/activities/live-courses/hepatitis-cvirus-courses/ for upcoming workshops.

HIV Prevention, Sexual Health, and Primary Care in 2019

• This brand new educational effort will focus on maintaining health for people with or at risk for HIV infection. This will include initiating and monitoring the use of prexposure prophylaxis (PrEP), antiretroviral therapy in conception and pregnancy, and appropriate vaccines against preventable

diseases and complications. This course will address the rise in sexually transmitted infections (STIs) as the increase in PrEP use is coinciding with a decrease in safer sex practices. Further, a shift in primary responsibility of for managing PrEP and STIs from HIV and infectious disease clinicians to primary care and internal medicine practitioners is driving the need for education around PrEP, STIs, and prevention throughout the medical community. This course has been designed to address that need. Visit www.iasusa.org/activities/live-courses/ for more

www.iasusa.org/activities/live-courses/ for more information.

Webinars

The IAS–USA offers state-of-the-art CME webinars led by nationally and internationally recognized faculty.

Each webinar lasts 75 to 90 minutes and addresses a current topic in HIV or HCV infection prevention and management and the treatment of concomitant conditions. Archived webinars now offer CME credit.

Conference on Retroviruses and Opportunistic Infections

The IAS–USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014, CROI 2015, CROI 2016, CROI 2017, CROI 2018, and CROI 2019 are available at www.CROIconference.org.

CROI 2020 will be held in Boston, Massachusetts, from March 8 to March 11, 2020.

Topics in Antiviral Medicine™

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine*[™] 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of patients with HIV or other viral infections. The journal offers CME credit and is indexed on *Index Medicus*/MEDLINE. To be added to our email list, please create an account on the IAS–USA website at www.iasusa.org. See the FAQ page for additional information on how to create an account. Subscriptions are complimentary and available in electronic format.

Treatment and Testing Guidelines

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is

International Antiviral Society–USA (Continued)

lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published. Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, are published biannually in the *Journal of the American Medical Association*. Visit

www.iasusa.org/resources/guidelines for updates.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, were published in the *Journal of the American Medical Association* in July 2018 (Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society– USA panel. *JAMA*. 2018;320[4]:379-396). *JAMA* offers free access to the paper at

https://jamanetwork.com/journals/jama/articleabstract/2688574. The paper includes updated

recommendations for the use of antiretroviral therapy in adults with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using antiretroviral drugs for preventing HIV among those at risk, including preexposure and postexposure prophylaxis.

Drug Resistance Mutations Projects

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. The information on relevant mutations is collected and

reviewed by a panel of acknowledged leaders in the field. This information, last updated in January 2017, is available in *Topics in Antiviral Medicine*[™], on pocket reference cards (available from the IAS–USA), and on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/. *Cases on the Web*

Cases on the Web (COW) is a series of case-driven Internet-based CME activities sponsored by the IAS– USA to offer physicians convenient online access to enduring material and top-quality education. The *COW* program provides basic and advanced-level educational activities that are offered for CME credit for as long as each *COW* is active, after which time they remain available in the *COW* archive for reference use only. Visit www.iasusa.org/activities/cases-on-the-web/activecows/ for a current list of *COW* activities.

Podcasts

Some past IAS–USA live CME courses are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations. Please note that these podcasts do not offer CME credit.

Key Slides

The IAS–USA offers a collection of downloadable key slides from presentations at conferences or past IAS–USA live courses. Presenters have selected the slides they consider the most informative and relevant. Key slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.

For information about any of these programs, please contact the IAS–USA. Phone: (415) 544-9400 • Fax: (415) 544-9401 E-mail: registration@iasusa.org • Website: www.iasusa.org



www.iasusa.org